The short version of circadian clock fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-26. Anything still debated is marked as such rather than presented as settled.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
== Dietary recommendations == Various national and international organizations concerned with nutrition and health have standards for copper intake at levels judged to be adequate for maintaining good health. These standards are periodically changed and updated as new scientific data become available. The standards sometimes differ among countries and organizations.
== History == Ember was founded in 2001 by Andrew Wheeler and Robert Poor. Both were students at MIT when they founded Ember with $3 million in seed funding led by Polaris Venture Partners with DFJ New England, Stata Venture Partners, and Bob Metcalfe. The company began by making mesh networking software for other companies' microchips and has since evolved to manufacturing Zigbee compliant chips itself. In 2003, Ember released its first chip, the EM2420, which was fully compliant with IEEE 802.15.4-2003 standards. Since then, Ember has released the EM260 Zigbee network co-processor and the EM250, Zigbee system-on-chip (SoC), and EmberZNet Zigbee Software in 2005. In 2007, the EmberZNet PRO was launched to provide software that supports the Zigbee PRO Feature Set. The Smart Energy Suite and new versions of Zigbee Development Tools came out in 2008. In 2009, Ember released its third generation chips, the EM300 series. In May 2012, Ember was acquired by Silicon Labs.
== Role in copper homeostasis == In mammals cellular Cu levels are regulated by CCS's interaction with the 26S proteasome. During times of Cu excess CCS delivers Cu to XIAP and primes the complex for auto-ubiquitination and subsequent degradation. Expression of SOD1 is not modified by Cu availability but by CCS ability to deliver Cu. Knockouts of CCS (Δccs) show 70-90% decrease in SOD1 activity as well as increased expression of Cu binding proteins, namely, MT-I, MT-II, ATOX1, COX17, ATP7A to, presumably, reduce the amount of free Cu. Cells with CCS mutants have been shown to display ALS like symptoms. Moreover, SOD1 mutants that have altered interactions with CCS have been shown to display misfolding and aggregation.
=== Two-step mechanism – autocatalysis model === In 1997, Finke and Watzky proposed a new kinetic model for the nucleation and growth of nanoparticles. This 2-step model suggested that constant slow nucleation (occurring far from supersaturation) is followed by autocatalytic growth where dispersity of nanoparticles is largely determined. This F-W (Finke-Watzky) 2-step model provides a firmer mechanistic basis for the design of nanoparticles with a focus on size, shape, and dispersity control. The model was later expanded to a 3-step and two 4-step models between 2004 and 2008. Here, an additional step was included to account for small particle aggregation, where two smaller particles could aggregate to form a larger particle. Next, a fourth step (another autocatalytic step) was added to account for a small particle agglomerating with a larger particle. Finally in 2014, an alternative fourth step was considered that accounted for a atomistic surface growth on a large particle.
Homosexuality is illegal in Malaysia, and authorities have imposed punishments such as caning and imprisonment. Human trafficking and sex trafficking in Malaysia are significant problems. There have also been cases of vigilante executions and beatings against LGBT individuals in Malaysia. The illegality of homosexuality in Malaysia has also been the forefront of Anwar Ibrahim's sodomy trials, which Anwar has called politically motivated, a characterisation supported by the Working Group on Arbitrary Detention, along with Amnesty International and the Human Rights Watch. The death penalty is in use for serious crimes such as murder, terrorism, and drug trafficking, some of which were once mandatory. However, in July 2023, following the passing of the Abolition of Mandatory Death Penalty Act 2023, mandatory death penalty was abolished for all crimes in Malaysia, thereby allowing judges to impose the capital punishment at their own discretion and on a case-by-case basis. The new law also abolished all natural life imprisonment, replacing it with 30 to 40 years prison terms instead.
Sources: en.wikipedia.org
== Reception == PC Zone reviewed the original mod version of the game, calling its maps "well-designed, well-crafted and large." However, they criticized the game's short-ranged weapons as "underpowered," calling it "far more satisfying to play medium to long-range." Phil Savage of PC Gamer called the game "unapologetically old-school FPS" and "worth checking out, if just for the fast and silly FPS action," but criticized it as "pretty janky in places." Christopher Livingston of the same publication awarded it "Mod of the Week," praising the dual-wielding mechanic and calling the game "a whole lot of fun."
FIAU is then phosphorylated stepwise: thymidine kinase (TK) converts FIAU to FIAU-monophosphate (FIAU-MP), then thymidylate kinase (TMPK) forms FIAU-diphosphate (FIAU-DP) and finally nucleoside-diphosphate kinase (DPK) produces FIAU-triphosphate (FIAU-TP). FIAU-TP can be incorporated into viral or cellular DNA (figure 4). In addition, thymidylate synthase (TS) has the potential to de-iodinate FIAU to FAU and then subsequently methylate FAU to FMAU monophosphate. FMAU monophosphate can subsequently be converted into FMAU diphosphate by thymidine monophosphate kinase (TMPK). Finally, FMAU diphosphate can be converted into FMAU triphosphate by the enzyme diphosphate kinase (DPK) with the purpose of incorporation into the viral or cellular DNA. FIAU does not exist as only one compound inside the cell, its metabolites can also contribute and FAU can ultimately be incorporated as FMAU in whole cells.
In molecular biology, and more importantly high-throughput DNA sequencing, a chimera is a single DNA sequence originating when multiple transcripts or DNA sequences get joined. Chimeras can be considered artifacts and be filtered out from the data during processing to prevent spurious inferences of biological variation. However, chimeras should not be confused with chimeric reads, which are generally used by structural variant callers to detect structural variation events and are not always an indication of the presence of a chimeric transcript or gene. In a different context, the deliberate creation of artificial chimeras can also be a useful tool in molecular biology. For example, in protein engineering, "chimeragenesis" (forming chimeras between proteins that are encoded by homologous cDNAs) is one of the "two major techniques used to manipulate cDNA sequences". For gene fusions that occur through natural processes, see chimeric genes and fusion genes.
=== Chemical properties === Like the lanthanides, all actinides are highly reactive with halogens and chalcogens; however, the actinides react more easily. Actinides, especially those with a small number of 5f-electrons, are prone to hybridization. This is explained by the similarity of the electron energies at the 5f, 7s and 6d shells. Most actinides exhibit a larger variety of valence states, and the most stable are +6 for uranium, +5 for protactinium and neptunium, +4 for thorium and plutonium and +3 for actinium and other actinides. Actinium is chemically similar to lanthanum, which is explained by their similar ionic radii and electronic structures. Like lanthanum, actinium almost always has an oxidation state of +3 in compounds, but it is less reactive and has more pronounced basic properties. Among other trivalent actinides Ac3+ is least acidic, i.e. has the weakest tendency to hydrolyze in aqueous solutions. Thorium is rather active chemically. Owing to lack of electrons on 6d and 5f orbitals, tetravalent thorium compounds are colorless. At pH < 3, solutions of thorium salts are dominated by the cations [Th(H2O)8]4+. The Th4+ ion is relatively large, and depending on the coordination number can have a radius between 0.95 and 1.14 Å. As a result, thorium salts have a weak tendency to hydrolyse. The distinctive ability of thorium salts is their high solubility both in water and polar organic solvents. Protactinium exhibits two valence states; the +5 is stable, and the +4 state easily oxidizes to protactinium(V).
== Honours and awards == Freeman was recognised for his professional achievements with Fellowships in the Royal Australian Chemical Institute (RACI) in 1968, the Royal Society of Chemistry in 1984, and the Australian Academy of Science in 1984. Freeman's contributions were also recognised by the Australian Government with a Centenary Medal in 2001 for "service to Australian society and science in chemistry" and with his appointment as a Member of the Order of Australia in June 2005 for "service to science and scientific research in the field of bio-inorganic chemistry, particularly through the establishment and development of the discipline of crystallography in Australia". Freeman received numerous awards over his long career. In 1980, Freeman received the Burrows Award, the premier award of the Inorganic Chemistry Division of the RACI. He was also awarded the 1999 Leighton Memorial Medal which is "the RACI's most prestigious medal and is awarded in recognition of eminent services to chemistry in Australia in the broadest sense." In 2007, he received both the Australian Academy of Science's Craig Medal and an RACI Distinguished Fellowship.
Sources: en.wikipedia.org
still holds, the surface energy (γ) predicted by Griffith's theory is usually unrealistically high. A group working under G. R. Irwin at the U.S. Naval Research Laboratory (NRL) during World War II realized that plasticity must play a significant role in the fracture of ductile materials. In ductile materials (and even in materials that appear to be brittle), a plastic zone develops at the tip of the crack. As the applied load increases, the plastic zone increases in size until the crack grows and the elastically strained material behind the crack tip unloads. The plastic loading and unloading cycle near the crack tip leads to the dissipation of energy as heat. Hence, a dissipative term has to be added to the energy balance relation devised by Griffith for brittle materials. In physical terms, additional energy is needed for crack growth in ductile materials as compared to brittle materials. Irwin's strategy was to partition the energy into two parts:
The first widely accepted set of classification criteria for research purposes was elaborated in 1990 by the Multicenter Criteria Committee of the American College of Rheumatology. These criteria, which are known informally as "the ACR 1990", defined fibromyalgia according to the presence of the following criteria:
Muscular dystrophy (MD) is a genetically and clinically heterogeneous group of rare neuromuscular diseases that cause progressive weakness and breakdown of skeletal muscles over time. The disorders differ as to which muscles are primarily affected, the degree of weakness, how fast they worsen, and when symptoms begin. Some types are also associated with problems in other organs. Over 30 different disorders are classified as muscular dystrophies. Of those, Duchenne muscular dystrophy (DMD) accounts for approximately 50% of cases and affects males beginning around the age of four. Other relatively common muscular dystrophies include Becker muscular dystrophy, facioscapulohumeral muscular dystrophy, and myotonic dystrophy, whereas limb–girdle muscular dystrophy and congenital muscular dystrophy are themselves groups of several – usually extremely rare – genetic disorders. Muscular dystrophies are caused by mutations in genes, usually those involved in making muscle proteins. The muscle protein dystrophin is in most muscle cells and works to strengthen the muscle fibers and protect them from injury as muscles contract and relax. It links the muscle membrane to the thin muscular filaments within the cell. Dystrophin is an integral part of the muscular structure. An absence of dystrophin can cause impairments: healthy muscle tissue can be replaced by fibrous tissue and fat, causing an inability to generate force. Respiratory and cardiac complications can occur as well. These mutations are either inherited from parents or may occur spontaneously during early development.
=== Crime and punishment === In Green Lantern (vol. 3) #54 (August 1994), Major Force kills Alexandra DeWitt, girlfriend of Green Lantern Kyle Rayner, and stuffs her remains in a refrigerator for Kyle to find. Kyle tortures Major Force after their fight, but is stopped by the Los Angeles Police Department. In an issue of Guy Gardner: Warrior, Major Force seemingly kills Guy Gardner's mother in the same manner as Alex. Gardner, who has awakened his Vuldarian abilities, kills Major Force with a shifted weapon's edge. The Quorum, who previously hired Major Force to harass Rayner and Gardner, resurrect him and enhance him with Vuldarian DNA. Major Force kills Arisia Rrab, a Green Lantern and friend of Gardner, as a declaration of war against him.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.